Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis.

Alogliptin drug lymphocyte stimulation test gallium-67 scintigraphy interstitial nephritis minimal change nephrotic syndrome

Journal

Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300

Informations de publication

Date de publication:
Historique:
entrez: 1 8 2020
pubmed: 14 3 2019
medline: 14 3 2019
Statut: epublish

Résumé

Alogliptin is one of the dipeptidyl peptidase-4 inhibitors used to treat patients with type 2 diabetes. Little is known about the nephrotoxicity associated with alogliptin, such as nephrotic syndrome or interstitial nephritis. We report a biopsy-proven rare case of minimal change nephrotic syndrome and interstitial nephritis induced by alogliptin. A 68-year-old man who had been prescribed alogliptin was hospitalized for nephrotic syndrome. On admission, serum creatinine level was elevated with increased urinary β

Identifiants

pubmed: 32734188
doi: 10.1016/j.xkme.2019.03.001
pii: S2590-0595(19)30020-2
pmc: PMC7380391
doi:

Types de publication

Case Reports

Langues

eng

Pagination

75-78

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 The Authors.

Références

P T. 2014 Mar;39(3):186-202
pubmed: 24790396
J Clin Tuberc Other Mycobact Dis. 2017 Feb 10;7:1-12
pubmed: 31723695
Nat Rev Nephrol. 2010 Aug;6(8):461-70
pubmed: 20517290
Clin Kidney J. 2015 Oct;8(5):516-23
pubmed: 26413275
Clin J Am Soc Nephrol. 2007 Mar;2(2):222-30
pubmed: 17699417
PLoS One. 2011;6(12):e28096
pubmed: 22194808
BMC Geriatr. 2017 Oct 16;17(Suppl 1):226
pubmed: 29047372
Nephrol Dial Transplant. 2004 Jan;19(1):8-11
pubmed: 14671029
Am J Med. 2012 Feb;125(2):118-25
pubmed: 22269612
BMC Nephrol. 2018 Mar 5;19(1):52
pubmed: 29506491
Ann Pharmacother. 2013 Nov;47(11):1532-9
pubmed: 24285765
N Engl J Med. 2007 Nov 22;357(21):2153-65
pubmed: 18032765
Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi52-8
pubmed: 12953043
Trends Immunol. 2003 Jul;24(7):376-9
pubmed: 12860528
Clin Kidney J. 2016 Feb;9(1):76-81
pubmed: 26798465
Front Immunol. 2014 Nov 03;5:549
pubmed: 25404930
Intern Med. 2008;47(23):2083-5
pubmed: 19043266
Front Pharmacol. 2017 Nov 15;8:835
pubmed: 29187821
J Am Soc Nephrol. 2006 Sep;17(9):2533-45
pubmed: 16885408

Auteurs

Hisato Shima (H)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Takuya Okamoto (T)

Department of Laboratory, Kawashima Hospital, Tokushima.

Manabu Tashiro (M)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Tomoko Inoue (T)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Chiaki Masaki (C)

Department of Laboratory, Kawashima Hospital, Tokushima.

Hiroaki Tada (H)

Department of Laboratory, Kawashima Hospital, Tokushima.

Norimichi Takamatsu (N)

Department of Laboratory, Kawashima Hospital, Tokushima.

Kazuhiko Kawahara (K)

Kamojima-Kawashima Clinic, Yoshinogawa, Tokushima, Japan.

Kazuyoshi Okada (K)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Toshio Doi (T)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Jun Minakuchi (J)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Shu Kawashima (S)

Department of Kidney Disease, Kawashima Hospital, Tokushima.

Classifications MeSH